a dollar a dose, three suppliers

Problem statement

Benzathine benzylpenicillin (BPG) is a seventy-year-old long-acting injectable penicillin that is "the sole treatment recommended by the World Health Organization" to prevent mother-to-child transmission of syphilis and the standard secondary prophylaxis for rheumatic heart disease. Authors from WHO, the U.S. CDC, the Clinton Health Access Initiative and the World Heart Federation report that "by 2016, only three Chinese API manufacturers remained, continuing to supply to the global market today," while CHAI estimated at least 30 companies were producing the finished product in 2016, most for low- and middle-income markets where "prices for BPG in these markets are low, typically less than US$1 per dose." Because "commercially producing BPG is not considered profitable, leading to prolonged order times and large minimum orders," and because "the global community ... rarely had a comprehensive view" of demand, the market swings between glut and shortage: between 2014 and 2016 at least 39 countries reported BPG shortages, and in 2023 the United States — where "one supplier controls the entire market" — was again short during a syphilis surge. The unsolved problem is a structurally thin, low-margin, three-supplier API market for a medicine that more than 40 million people a year depend on, with no mechanism that lets buyers see demand or lets suppliers trust it.

Why this matters

Mother-to-child syphilis transmission "causes >350 000 adverse birth outcomes" a year, two-thirds of them stillbirths or neonatal deaths, and more than 39 million people live with rheumatic heart disease with about 320,000 deaths annually — both concentrated in low-resource settings. When BPG runs out, "patients receiv[e] non-recommended therapies," and the authors link the 2014–2016 shortages to increases in congenital syphilis. The market is also far smaller than the need: CHAI's estimate of global demand, 74–100 million 1.2-million-unit doses in 2016, is "less than half of what is required," with an estimated 200 million doses a year needed for rheumatic heart disease alone — so any effort to close the treatment gap would immediately collide with a supply base that cannot flex. Concentration compounds fragility: "API manufacturing is concentrated in two regions of China where environmental regulations have disrupted production in the past," and "limited compliance with good manufacturing practices further increases the risk of production suspension by international regulatory authorities."

What’s been tried and why it hasn’t worked

The 2014–2016 shortages "were triggered by concurrent and unrelated events that disrupted the API supply from two of the three active manufacturers," and the responses since have been visibility and quality measures rather than market structure: WHO surveys of national availability (a 2019 survey found six countries still short; WHO was again soliciting country data in 2023), WHO prequalification technical assistance (yet "as of July 2023, only one BPG product has received WHO prequalification"), and donor procurement channels such as the Global Fund and PEPFAR guidance requiring syphilis treatment availability. The authors are explicit that "while proposed mitigation actions contribute to the response, they fail to offer a structural solution to prevent shortages." The reasons are economic and informational: price ceilings, competition among many small buyers of non-quality-assured product, and low volumes "undermine economic incentives to supply quality-assured product that is costly to produce"; producers show "inflexibility in filling orders"; and even where a prequalified product exists, "availability of a quality-assured product may not stimulate new demand or buyers that opt for a switch from non-PQ products unless accompanied by wider market intervention." National-level obstacles add friction — South Africa has procured BPG since 2016 on temporary Section 21 authorisations because new suppliers struggle to register.

What would unlock progress

The authors' own prescription is market shaping: country-level forecasting built on disease surveillance ("robust disease surveillance data to quantify national demand, particularly for RHD and syphilis"), monitoring of stock levels and the number of authorised suppliers ("single-supplier nations are more susceptible to shortages"), global market transparency with direct manufacturer engagement, faster shortage notification, a maintained response plan with access to a backstop supply, and — structurally — a large payer or coordinated group of payers that aggregates demand for quality-assured product, as was done in HIV and vaccine markets. The transferable pattern is vaccine-style demand pooling and long-term supply agreements applied to an off-patent, sub-dollar antibiotic; the missing piece is the demand-visibility layer that would let a fourth or fifth API producer, or a stockpile, be financed on evidence rather than hope.

Entry points for student teams

A data team could prototype the demand-visibility tool the paper says does not exist: an open model that converts published syphilis (including antenatal) and rheumatic heart disease burden estimates plus public procurement records into country-level BPG dose demand and supplier-count risk scores, and shows where a single-supplier country meets a rising caseload. A market-design team could model the economics of BPG API production — minimum order sizes, batch cadence, price per dose — to size the offtake commitment or stockpile that would make a fourth quality-assured API line viable, drawing on published vaccine advance-market-commitment designs. A regulatory team could map registration pathways for BPG in a set of high-burden countries and design a collaborative-registration route for prequalified product. Relevant skills: epidemiology and health-data analysis, health economics/market shaping, pharmaceutical regulation, supply-chain modelling.